8-K: KORU Medical Systems Amends Credit Facility

KORU Medical Systems, Inc. has amended its loan and security agreement with HSBC Ventures USA Inc., extending credit facility maturities and adjusting covenants.

Summary

• KORU Medical Systems, Inc. (the Company) entered into an amendment to its loan and security agreement with HSBC Ventures USA Inc. on March 30, 2026.
• The amendment modifies a revolving credit facility of up to $5,000,000 and a term loan facility of up to $5,000,000.
• The maturity date for the revolving credit facility has been extended to March 30, 2028.
• The interest-only period for the term loan has been extended to June 30, 2027, with a potential further extension to December 31, 2027, contingent on achieving certain EBITDA milestones.
• The term loan maturity date has been extended to December 1, 2029.
• The interest rate floor for both facilities has been lowered to 5.50% from 6.50%.
• The adjusted quick ratio covenant has been removed and replaced with a remaining months liquidity covenant of at least twelve months, tested monthly once the revolving credit facility is drawn, with a provision for compliance if trailing three-month average Adjusted EBITDA is positive.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as the company has secured more favorable credit terms and extended maturities, though the achievement of certain benefits is contingent on future performance.

Positives

• Extended maturity dates for both the revolving credit facility (to March 30, 2028) and the term loan (to December 1, 2029), providing greater financial flexibility.
• Lowered interest rate floor to 5.50% from 6.50%, potentially reducing borrowing costs.
• Replaced a potentially restrictive adjusted quick ratio covenant with a more flexible remaining months liquidity covenant, which includes a positive EBITDA override.
• The company has not yet drawn on the credit facility, indicating current liquidity is sufficient.

Negatives

• The company must achieve positive Adjusted EBITDA for two consecutive fiscal quarters by June 30, 2027, to secure the full extension of the term loan's interest-only period and draw period end date.
• The new liquidity covenant requires maintaining at least twelve months of liquidity, tested monthly once the revolving credit facility is drawn, which could become a compliance challenge if cash reserves dwindle.

Risks

• Failure to achieve the specified Adjusted EBITDA milestones by June 30, 2027, could result in earlier maturity of the interest-only period and a shorter draw period.
• The monthly testing of the remaining months liquidity covenant could trigger a default if the company's cash position or EBITDA performance deteriorates significantly after drawing on the credit facility.
• The requirement to maintain a minimum of 75% of depository and operating accounts, cash equivalents, and excess cash with HSBC or its affiliates, and to exclusively use HSBC for business credit cards and letters of credit, could limit banking options.

Future Outlook

The amendment provides KORU Medical Systems with extended debt maturities and adjusted covenants. The ability to further extend the interest-only period for the term loan hinges on achieving positive Adjusted EBITDA milestones, indicating a focus on operational performance to secure favorable financing terms.

Industry Context

StockSavvy.ai notes that extending credit facility maturities and adjusting covenants are common strategies for companies seeking to improve financial flexibility and manage debt obligations, especially in industries with capital-intensive operations or cyclical revenue streams. The focus on EBITDA milestones reflects a trend towards performance-based lending.

Stakeholder Impact

• Shareholders: The extended credit facility and potentially lower interest rate floor could improve financial stability and reduce interest expense, positively impacting profitability.
• Creditors: The amendment provides greater assurance of the company's ability to service its debt obligations due to extended maturities and adjusted covenants.
• Lender (HSBC Ventures USA Inc.): The lender has modified the terms of its agreement, potentially accepting a lower interest rate floor and a different covenant structure in exchange for continued business and revised risk parameters.

Next Steps

• Monitor KORU Medical Systems' Adjusted EBITDA performance to assess the likelihood of achieving the EBITDA Milestone Event.
• Track the company's liquidity position to ensure compliance with the remaining months liquidity covenant once the revolving credit facility is drawn.
• Observe any future draws on the credit facility.

Key Dates

Recommendation

The filing details an amendment to an existing credit facility, which is a routine financial maneuver. While it offers some positive adjustments like extended maturities and a lower interest rate floor, it does not provide new operational or financial performance data that would warrant a change in investment recommendation. The company's future performance remains contingent on achieving specific EBITDA milestones, making it prudent to maintain a 'hold' position pending further operational updates.

Keywords

KORU Medical Systems, HSBC Ventures USA Inc., Loan and Security Agreement, Credit Facility Amendment, Revolving Credit Facility, Term Loan, EBITDA Milestone, Liquidity Covenant